7JN

Poolbeg Pharma DB:7JN Stock Report

Last Price

€0.09

Market Cap

€50.7m

7D

-4.3%

1Y

4.7%

Updated

27 Jan, 2023

Data

Company Financials +

7JN Stock Overview

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.

7JN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.09
52 Week HighUK£0.11
52 Week LowUK£0.037
Beta0
1 Month Change55.17%
3 Month Change36.36%
1 Year Change4.65%
3 Year Changen/a
5 Year Changen/a
Change since IPO-3.02%

Recent News & Updates

Recent updates

Shareholder Returns

7JNDE PharmaceuticalsDE Market
7D-4.3%-1.3%-1.1%
1Y4.7%1.9%-11.6%

Return vs Industry: 7JN exceeded the German Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: 7JN exceeded the German Market which returned -11.6% over the past year.

Price Volatility

Is 7JN's price volatile compared to industry and market?
7JN volatility
7JN Average Weekly Movement18.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7JN is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: 7JN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20217Jeremy Skillingtonhttps://www.poolbegpharma.com

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
7JN fundamental statistics
Market Cap€50.73m
Earnings (TTM)-€3.55m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
7JN income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.11m
Earnings-UK£3.11m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0062
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 7JN perform over the long term?

See historical performance and comparison